RIBOMIC Inc. (4591.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.3x

Market Cap

JPY 4.42B

MomentumView details →

1D Return

−5.68%

YTD Return

+8.97%

RSI (14)

54.4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.3x

Market Cap

JPY 4.42B

RSI (14)

54.4

MomentumView details →

1D Return

−5.68%

YTD Return

+8.97%

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−32.30%

ROA (TTM)

−30.76%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−97.68%

EPS YoY

+9.10%

FCF YoY

—

Revenue CAGR 3Y

−70.76%

EPS CAGR 3Y

+12.16%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

20.68x

Quick Ratio

20.68x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

−1.04B

Op. CF (TTM)

—

Next earningsNov 17, 2026 →

Latest newsMore news →

Ribomic announced that its domestic Phase 3 clinical trial for an achondroplasia treatment drug has reached the planned number of trial sites, with cumulative 16 institutions now able to enroll patients after obtaining IRB approvals at 6 new facilities.12d ago

Ribomic's phase 3 clinical trial information for an achondroplasia treatment was published on the MHLW system.57d ago

Similar companies

Kubota Pharmaceutical Holdings Co.,Ltd.4596.T D.Western Therapeutics Institute, Inc.4576.T TMS Co.,Ltd.4891.T Chordia Therapeutics Inc.190A.T Cyfuse Biomedical K.K.4892.T Medrx Co.,Ltd.4586.T Find similar companies →

Latest newsMore news →

Ribomic announced that its domestic Phase 3 clinical trial for an achondroplasia treatment drug has reached the planned number of trial sites, with cumulative 16 institutions now able to enroll patients after obtaining IRB approvals at 6 new facilities.12d ago Ribomic's phase 3 clinical trial information for an achondroplasia treatment was published on the MHLW system.57d ago